An individual patient data meta-analysis of randomized melanoma trials, covering a wide range of IFN dose regimens, suggested that the benefits of IFN are independent of dose or therapy duration, and translate into an absolute OS benefit of approximately 3% (95% confidence interval [CI]: 1%-5%) at 5 years [10]. This evidence concerns the gene IFNA1 and melanoma.